Vol. 4 No. 11 (2024): November
Reimbursement Reviews

Aflibercept 8 mg/0.07 mL (Eylea HD)

Published November 7, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses aflibercept (Eylea HD) 8 mg (0.07 mL), solution for intravitreal injection.
  • Indication: For the treatment of neovascular (wet) age-related macular degeneration (nAMD).